AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Exelixis Q2 2025 Earnings Preview: Revenue Down 9.2% YoY, EPS Down 23.8% YoY
ByAinvest
Sunday, Jul 27, 2025 12:59 am ET1min read
Exelixis is set to announce Q2 2025 earnings on July 28th, after market close. The consensus EPS estimate is $0.64, down 23.8% YoY, and revenue is expected to be $578.31M, a 9.2% YoY decline. Over the past two years, Exelixis has outperformed its peers in terms of revenue growth, and its stock has consistently beaten analyst expectations.
Exelixis Inc. (EXEL), a biopharmaceutical company, is set to release its Q2 2025 earnings on July 28th, after market close. The consensus earnings per share (EPS) estimate is $0.64, representing a year-over-year (YoY) decline of 23.8%, while revenue is expected to be $578.31 million, down 9.2% YoY [1].Over the past two years, Exelixis has consistently outperformed EPS estimates 50% of the time and revenue estimates 67% of the time [2]. This historical performance suggests that the company may be able to beat the consensus EPS estimate once again. However, investors should remain cautious, as the actual earnings report could still impact the stock price.
Analysts are optimistic about Exelixis's prospects, with a consensus rating of "Buy" and an average one-year price target of $48.5, indicating a potential 8.28% upside [2]. The company's strong revenue growth and gross profit margins have positioned it favorably compared to its peers, although its return on equity is relatively low [2].
Exelixis' stock has been performing well, with a 21% increase over the past three months. The company's return on equity (ROE) is 30%, which is higher than the industry average of 16% [3]. This high ROE, combined with the company's impressive earnings growth of 22% over the past five years, indicates that Exelixis is efficiently utilizing its shareholders' capital.
Investors should closely monitor Exelixis's earnings call for any updates on business conditions and future guidance. The company's ability to exceed earnings estimates and provide positive forward-looking statements could drive the stock price higher. Conversely, any disappointments could lead to a decrease in the stock price.
References:
[1] https://www.ainvest.com/news/exelixis-q2-2025-earnings-preview-expectations-performance-2507/
[2] https://www.benzinga.com/insights/earnings/25/07/46633993/uncovering-potential-exelixiss-earnings-preview
[3] https://finance.yahoo.com/news/exelixis-inc-nasdaq-exel-stocks-181743783.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet